title: Long-term survival after significant treatment reduction in a patient with CBF-AML.
authors.forename: E M C
authors.initials: EM
authors.lastname: Driessen
authors.forename: V H J
authors.initials: VH
authors.lastname: van der Velden
authors.forename: C E
authors.initials: CE
authors.lastname: Catsman-Berrevoets
authors.forename: M M
authors.initials: MM
authors.lastname: van den Heuvel-Eibrink
authors.forename: A
authors.initials: A
authors.lastname: Beishuizen
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D050658:Core Binding Factor beta Subunit / Q000235:genetics; D050660:Core Binding Factors / Q000235:genetics*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality*; D008297:Male; D018995:Myosin Heavy Chains / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D050658:Core Binding Factor beta Subunit; D050660:Core Binding Factors; C509903:MYH11 protein, human; D018995:Myosin Heavy Chains